RU2404795C2 - Способы лечения почечно-клеточной карциномы - Google Patents
Способы лечения почечно-клеточной карциномы Download PDFInfo
- Publication number
- RU2404795C2 RU2404795C2 RU2007132125/14A RU2007132125A RU2404795C2 RU 2404795 C2 RU2404795 C2 RU 2404795C2 RU 2007132125/14 A RU2007132125/14 A RU 2007132125/14A RU 2007132125 A RU2007132125 A RU 2007132125A RU 2404795 C2 RU2404795 C2 RU 2404795C2
- Authority
- RU
- Russia
- Prior art keywords
- des
- mutein
- amino acid
- sequence
- weeks
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64749605P | 2005-01-27 | 2005-01-27 | |
| US60/647,496 | 2005-01-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007132125A RU2007132125A (ru) | 2009-03-10 |
| RU2404795C2 true RU2404795C2 (ru) | 2010-11-27 |
Family
ID=36741121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007132125/14A RU2404795C2 (ru) | 2005-01-27 | 2006-01-27 | Способы лечения почечно-клеточной карциномы |
Country Status (13)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2370399A4 (en) * | 2008-12-11 | 2013-05-22 | Agency Science Tech & Res | GLUCOSE-PEG CONJUGATES TO REDUCE GLUCOSE TRANSPORT INTO A CELL |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EP3443979B2 (en) * | 2011-03-11 | 2026-05-20 | Assistance Publique - Hôpitaux De Paris | IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| US9669071B2 (en) * | 2011-03-11 | 2017-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating T lymphocytes with IL-2 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| EP3129493B1 (en) | 2014-04-09 | 2021-07-07 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
| EP3288576A4 (en) * | 2015-04-27 | 2019-01-16 | Susavion Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| KR102777151B1 (ko) * | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| MX2022008770A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Muteinas de la il2. |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| IL301612A (en) * | 2020-10-09 | 2023-05-01 | Synthorx Inc | Immuno oncology therapies with il-2 conjugates |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2174409C2 (ru) * | 1995-11-30 | 2001-10-10 | Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем | Способы и композиции для диагностики и лечения рака |
| WO2004002526A1 (en) * | 2002-07-01 | 2004-01-08 | Wilex Ag | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
-
2006
- 2006-01-27 ES ES06719806T patent/ES2432141T3/es not_active Expired - Lifetime
- 2006-01-27 CA CA002595959A patent/CA2595959A1/en not_active Abandoned
- 2006-01-27 BR BRPI0606774-3A patent/BRPI0606774A2/pt not_active Application Discontinuation
- 2006-01-27 KR KR1020077019556A patent/KR20070102576A/ko not_active Ceased
- 2006-01-27 WO PCT/US2006/003116 patent/WO2006081510A2/en not_active Ceased
- 2006-01-27 JP JP2007553304A patent/JP2008528621A/ja active Pending
- 2006-01-27 US US11/342,243 patent/US20070014765A1/en not_active Abandoned
- 2006-01-27 AU AU2006207987A patent/AU2006207987B2/en not_active Ceased
- 2006-01-27 EP EP06719806.9A patent/EP1846020B1/en not_active Expired - Lifetime
- 2006-01-27 MX MX2007009012A patent/MX2007009012A/es active IP Right Grant
- 2006-01-27 CN CNA2006800067217A patent/CN101132809A/zh active Pending
- 2006-01-27 RU RU2007132125/14A patent/RU2404795C2/ru not_active IP Right Cessation
-
2007
- 2007-07-26 IL IL184865A patent/IL184865A/en active IP Right Grant
-
2009
- 2009-07-28 US US12/460,991 patent/US8012465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 JP JP2011266809A patent/JP2012046552A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2174409C2 (ru) * | 1995-11-30 | 2001-10-10 | Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем | Способы и композиции для диагностики и лечения рака |
| WO2004002526A1 (en) * | 2002-07-01 | 2004-01-08 | Wilex Ag | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
Non-Patent Citations (2)
| Title |
|---|
| AMATO R.J., SCHELL J. et al: Phase II study of thalidomide+interleukm-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc ASCO 22:387, (abstr #1556), 2003. VERRA N. et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma., Br J Cancer. 2003 May 6; 88(9): 1346-1351. * |
| SLEIJFER D.T. et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced., J Clin OncoL, 1992; 10: 1119-1123. * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0606774A2 (pt) | 2009-07-14 |
| IL184865A0 (en) | 2007-12-03 |
| IL184865A (en) | 2011-04-28 |
| EP1846020B1 (en) | 2013-08-21 |
| AU2006207987B2 (en) | 2011-09-15 |
| AU2006207987A1 (en) | 2006-08-03 |
| JP2012046552A (ja) | 2012-03-08 |
| MX2007009012A (es) | 2007-09-14 |
| CA2595959A1 (en) | 2006-08-03 |
| US20100316595A1 (en) | 2010-12-16 |
| RU2007132125A (ru) | 2009-03-10 |
| JP2008528621A (ja) | 2008-07-31 |
| KR20070102576A (ko) | 2007-10-18 |
| US8012465B2 (en) | 2011-09-06 |
| WO2006081510A3 (en) | 2007-01-18 |
| US20070014765A1 (en) | 2007-01-18 |
| CN101132809A (zh) | 2008-02-27 |
| ES2432141T3 (es) | 2013-11-29 |
| WO2006081510A2 (en) | 2006-08-03 |
| EP1846020A2 (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8012465B2 (en) | Methods for treating renal cell carcinoma | |
| JP6718494B2 (ja) | 癌を処置するためのペグ化il−10の使用 | |
| ES2276698T3 (es) | Composiciones farceuticas que contienen un polipeptido liquido estabilizado. | |
| ES2906615T3 (es) | Tratamiento derivado de citocinas con síndrome de fuga vascular reducido | |
| AU2010204552B2 (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| CN116251173A (zh) | 重组人血管内皮抑制素的用途 | |
| AU2014208224A1 (en) | New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein | |
| KR20140130705A (ko) | 체강액 저류 억제제 | |
| HK1172248A (en) | Use of pegylated il-10 to treat cancer | |
| HK1127553B (en) | Use of pegylated il-10 to treat cancer | |
| HK1201182B (en) | Pegylated il-10 for use in treating lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20210128 |